Title
Pathway to Stop Diabetes
Agencies
American Diabetes Association (ADA)
Description
Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research. Our Vision is simple yet revolutionary: find a new generation of brilliant scientists at the peak of their creativity, and provide them with freedom, autonomy, and the financial and professional resources to set them on the road to breakthrough discoveries.
This initiative enables scientists to advance not only their research, but also their careers. Pathway scientists have access to the Mentor Advisory Group, an annual Pathway symposia, select speaking opportunities, and innovative technologies, all designed to foster interactions and collaboration that will enable them to accelerate their research progress.
Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication. Pathway solicits nominations for candidates in all disciplines as applied to diabetes including medicine, biology, chemistry, computing, physics, mathematics and engineering. In addition, nomination of scientists from diverse backgrounds, including minority groups that are underrepresented in biomedical research, is strongly encouraged. Â
More Information
https://professional.diabetes.org/meetings/pathway-stop-diabetes®
Submission Limits
Candidates will be identified through nominations from U.S.-accredited academic and nonprofit research institutions.
Each institution is allowed a maximum of one nomination. The nomination can be in any one of the three available Pathway award types:
Initiator (for researchers in postdoctoral training)
Accelerator (for early-career diabetes investigators)
Visionary (for established investigators, new to diabetes).
Nominations must be on behalf of the institution and from an authorized institutional representative, such as the Nominating Committee Chair, Division Chair, Dean of Research, or President. Individual components of multi-component institutions (e.g. University of California Los Angeles and University of California Berkeley within the University of California system, or Harvard University and Beth Israel Deaconess Medical Center within the Harvard system) are sufficiently independent to be considered individual institutions. Institutions must have a unique DUNS and/or IPF number to be considered independent. The Pathway program seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective.
Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disea
Deadlines
Internal Notice of Intent |
Mar 16, 2018 |
Notification of Internal Competition |
Mar 17, 2018 |
Internal Pre-proposal |
Apr 6, 2018 |
Results of Internal Competition |
Apr 20, 2018 |
Agency Notice of Intent/Pre-proposal |
N/A |
Agency Proposal |
Jul 2, 2018
|
|